Mental Disorders Were Most Costly in U.S. in 2013

This article originally appeared here.
Share this content:
Mental Disorders Were Most Costly in U.S. in 2013
Mental Disorders Were Most Costly in U.S. in 2013

THURSDAY, May 26, 2016 (HealthDay News) -- Mental disorders were the most costly conditions in the United States in 2013, with a cost of $201 billion, according to a study published in the May issue of Health Affairs.

Charles Roehrig, Ph.D., from the Altarum Institute in Ann Arbor, Michigan, and examined the allocation of spending across medical conditions in the United States.

Roehrig notes that in 1996, the most costly medical conditions were heart conditions ($105 billion), followed by mental disorders ($79 billion). In 2004, these conditions had equal spending ($131 billion each), while in 2013, spending on mental disorders had exceeded that of heart conditions, with spending of $201 billion, compared with $147 billion on heart conditions. The average annual growth rate in spending on mental disorders was 5.6 percent, compared with 2 percent for spending on heart conditions. Most of the fastest-growing medical conditions in terms of spending were medical conditions associated with obesity; most of the spending growth rates were too high to be explained by obesity-induced increased disease prevalence, and were likely due to the introduction of expensive new treatments.

"A look ahead suggests that reductions in deaths from heart conditions and cerebrovascular disease are likely to drive spending on mental disorders even higher, as more people survive to older ages -- when mental disorders, such as dementia, become more prevalent," the author writes.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »